{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:13:30Z","timestamp":1789964010683,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1053\/j.seminhematol.2014.05.006","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T19:45:40Z","timestamp":1400183140000},"page":"228-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Immunomodulation and Immune Reconstitution in Chronic Lymphocytic Leukemia"],"prefix":"10.1053","volume":"51","author":[{"given":"John C.","family":"Riches","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2014.05.006_bib1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjh.12115","article-title":"New ways to separate graft-versus-host disease and graft-versus-tumour effects after allogeneic haematopoietic stem cell transplantation","volume":"160","author":"Kotsiou","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.V62.6.1289.1289","article-title":"Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia","volume":"62","author":"Pizzolo","year":"1983","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/1097-0320(20000615)42:3<188::AID-CYTO5>3.0.CO;2-Q","article-title":"Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population","volume":"42","author":"Goolsby","year":"2000","journal-title":"Cytometry"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0145-2126(97)00152-5","article-title":"Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment","volume":"22","author":"Van den Hove","year":"1998","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"Gorgun","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib10","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib11","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-08-448332","article-title":"Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide","volume":"121","author":"Ramsay","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T cell immunological synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib13","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","article-title":"Reduced frequencies and suppressive function of CD4+ CD25high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine","volume":"106","author":"Beyer","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/10428190902803677","article-title":"Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia","volume":"50","author":"Jak","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib15","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","article-title":"A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib16","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib17","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib18","first-page":"116","article-title":"A Phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in combination with rituximab and\/or bendamustine in patients with relapsed or refractory B-cell malignancies","author":"Flinn","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib19","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib20","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib21","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib22","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib23","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib25","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2012.42.8623","article-title":"Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia","volume":"31","author":"Badoux","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib27","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1365-2141.2009.08014.x","article-title":"Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells","volume":"148","author":"Idler","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib28","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/cncr.25748","article-title":"Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response","volume":"117","author":"Chanan-Khan","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib29","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3324\/haematol.2009.005835","article-title":"Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia","volume":"94","author":"Aue","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/clin.1995.1048","article-title":"Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens","volume":"75","author":"Dazzi","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib31","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1158\/0008-5472.CAN-11-3368","article-title":"Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule","volume":"72","author":"Castro","year":"2012","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib32","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib33","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib34","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"Fukuda","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nri2635","article-title":"Engineering lymphocyte subsets: tools, trials and tribulations","volume":"9","author":"June","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib36","doi-asserted-by":"crossref","first-page":"956304","DOI":"10.1155\/2010\/956304","article-title":"Chimeric antigen receptor-engineered T cells for immunotherapy of cancer","volume":"2010","author":"Cartellieri","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/CJI.0b013e3182811ce9","article-title":"Sleeping beauty system to redirect T-cell specificity for human applications","volume":"36","author":"Maiti","year":"2013","journal-title":"J Immunother"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib38","article-title":"Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia","volume":"2012","author":"Koehler","year":"2011","journal-title":"Adv Hematol"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib39","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib40","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib41","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib42","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib43","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib44","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib45","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib48","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2014.05.006_bib49","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2008.11.024","article-title":"Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells","volume":"33","author":"Boissel","year":"2009","journal-title":"Leuk Res"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196314000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196314000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:23:22Z","timestamp":1758522202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196314000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0037196314000328"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2014.05.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulation and Immune Reconstitution in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2014.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}